Physician profile
Toby Shawe
NPI 1851453765
$17,888.28
in general payments reported to CMS, 2019-2025
34 companies · $3,203 in 2025
The $3,203 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $1,272 · 2021: $2,303 · 2022: $2,954 · 2023: $3,183 · 2024: $3,241 · 2025: $3,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,420 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,419.52 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,942.63 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $3,477.55 | 2019-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $1,512.96 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $1,145.69 | 2019-2025 | |
| Leo Pharma INC. | $963.79 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $715.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $667.35 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $623.24 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $550.56 | 2021-2024 | Opzelura |
| Amgen INC. | $432.73 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $381.91 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $357.62 | 2022-2025 | Sotyktu |
| Pfizer INC. | $345.20 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $341.33 | 2022-2025 | |
| Ucb, INC. | $326.75 | 2019-2025 | Bimzelx, Cimzia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $270.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.47 | 2022-2024 | Spevigo |
| Organon LLC | $173.36 | 2025 | Vtama |
| Genentech USA, INC. | $170.52 | 2019-2024 | Actemra |
| Dermavant Sciences, INC. | $168.49 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $157.63 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.70 | 2019-2021 | |
| Revance Therapeutics, INC. | $126.14 | 2025 | Daxxify |
| Biofrontera INC. | $114.43 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $107.80 | 2019-2020 | |
| Almirall LLC | $86.95 | 2019-2025 | Seysara |
| Dermira, INC. | $77.07 | 2019-2021 | |
| Mission Pharmacal Company | $71.59 | 2020-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $62.07 | 2019-2023 | Valchlor |
| Botanix Sb INC | $61.20 | 2025 | Sofdra |
| Journey Medical Corporation | $42.98 | 2020-2023 | |
| Allergan, INC. | $13.16 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.10 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Shawe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.